Breaking Finance News

RBC Capital Markets announced Spark Therapeutics (NDAQ:ONCE), boosting its stock price target to $100.00 today

Just yesterday Spark Therapeutics (NDAQ:ONCE) traded 1.06% higher at $81.58. Spark Therapeutics’s 50-day moving average is $82.11 and its 200-day moving average is $71.89. The last stock price is up 14.33% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 136,664 shares of ONCE traded hands, down from an average trading volume of 354,500

In a report released on 9/15/2017 RBC Capital Markets increased the stock price target of Spark Therapeutics (NDAQ:ONCE) to $100.00 reporting a possible upside of 0.23%.

Previously on 8/17/2017, Evercore ISI released a statement about Spark Therapeutics (NDAQ:ONCE) increased the target price from $0.00 to $83.00. At the time, this indicated a possible upside of 0.08%.

Recent Performance Chart

Spark Therapeutics (NDAQ:ONCE)

Spark Therapeutics has 52 week low of $35.07 and a 52 week high of $85.26 and has a market capitalization of $0.

In addition to RBC Capital Markets reporting its stock price target, a total of 9 brokerages have issued a ratings update on the company. The average stock price target is $58.44 with 0 brokerages rating the stock a strong buy, 5 brokerages rating the stock a buy, 3 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 1 brokerage rating the stock a sell.

Brief Synopsis On Spark Therapeutics (NDAQ:ONCE)

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *